Back to top
more

Ocugen (OCGN)

(Delayed Data from NSDQ)

$1.33 USD

1.33
4,628,140

+0.01 (0.76%)

Updated Aug 31, 2026 04:00 PM ET

After-Market: $1.32 -0.01 (-0.75%) 5:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?

by Zacks Equity Research

Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.

Kinjel Shah headshot

5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026

by Kinjel Shah

MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors

Zacks Equity Research

Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

Ocugen (OCGN) delivered earnings and revenue surprises of -16.67% and +46.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Cooper Companies Q1 Earnings Likely to Reflect Seasonal Trends

by Zacks Equity Research

COO's fiscal first-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.

Kinjel Shah headshot

5 Biotech Breakthrough Stocks to Watch in 2025

by Kinjel Shah

It is a good idea to keep an eye on five biotech breakthrough stocks, MDMD, BEAM, ACLX, OCGN and INSM, as they may give great returns in the next 2-3 years

Zacks Equity Research

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ocugen (OCGN) delivered earnings and revenue surprises of 0% and 5.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up

by Zacks Equity Research

OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.